BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 23512947)

  • 1. Lipid metabolism genes in contralateral unaffected breast and estrogen receptor status of breast cancer.
    Wang J; Scholtens D; Holko M; Ivancic D; Lee O; Hu H; Chatterton RT; Sullivan ME; Hansen N; Bethke K; Zalles CM; Khan SA
    Cancer Prev Res (Phila); 2013 Apr; 6(4):321-30. PubMed ID: 23512947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer.
    Wang J; Shidfar A; Ivancic D; Ranjan M; Liu L; Choi MR; Parimi V; Gursel DB; Sullivan ME; Najor MS; Abukhdeir AM; Scholtens D; Khan SA
    Int J Cancer; 2017 Jun; 140(11):2484-2497. PubMed ID: 28263391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges in projecting clustering results across gene expression-profiling datasets.
    Lusa L; McShane LM; Reid JF; De Cecco L; Ambrogi F; Biganzoli E; Gariboldi M; Pierotti MA
    J Natl Cancer Inst; 2007 Nov; 99(22):1715-23. PubMed ID: 18000217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
    Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation.
    Van Laere SJ; Van der Auwera I; Van den Eynden GG; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
    Br J Cancer; 2007 Sep; 97(5):659-69. PubMed ID: 17700572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laser microdissection and microarray analysis of breast tumors reveal ER-alpha related genes and pathways.
    Yang F; Foekens JA; Yu J; Sieuwerts AM; Timmermans M; Klijn JG; Atkins D; Wang Y; Jiang Y
    Oncogene; 2006 Mar; 25(9):1413-9. PubMed ID: 16261164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor expression in benign breast ductal cells obtained from random periareolar fine needle aspiration correlates with menopausal status and cytomorphology index score.
    Sharma P; Kimler BF; Warner C; Metheny T; Xue Q; Zalles CM; Fabian CJ
    Breast Cancer Res Treat; 2006 Nov; 100(1):71-6. PubMed ID: 16791479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer.
    Wang Z; Dahiya S; Provencher H; Muir B; Carney E; Coser K; Shioda T; Ma XJ; Sgroi DC
    Clin Cancer Res; 2007 Nov; 13(21):6327-34. PubMed ID: 17975144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
    Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
    Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients.
    Naoi Y; Kishi K; Tanei T; Tsunashima R; Tominaga N; Baba Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S
    Breast Cancer Res Treat; 2011 Aug; 128(3):633-41. PubMed ID: 20803240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance.
    Karn T; Ruckhäberle E; Hanker L; Müller V; Schmidt M; Solbach C; Gätje R; Gehrmann M; Holtrich U; Kaufmann M; Rody A
    Breast Cancer Res Treat; 2011 Nov; 130(2):409-20. PubMed ID: 21203899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
    Habel LA; Shak S; Jacobs MK; Capra A; Alexander C; Pho M; Baker J; Walker M; Watson D; Hackett J; Blick NT; Greenberg D; Fehrenbacher L; Langholz B; Quesenberry CP
    Breast Cancer Res; 2006; 8(3):R25. PubMed ID: 16737553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns.
    Gruvberger S; Ringnér M; Chen Y; Panavally S; Saal LH; Borg A ; Fernö M; Peterson C; Meltzer PS
    Cancer Res; 2001 Aug; 61(16):5979-84. PubMed ID: 11507038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytologic atypia in the contralateral unaffected breast is related to parity and estrogen-related genes.
    Monahan DA; Wang J; Lee O; Revesz E; Taft N; Ivancic D; Hansen NM; Bethke KP; Zalles C; Khan SA
    Surg Oncol; 2016 Dec; 25(4):449-456. PubMed ID: 26856771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer.
    Kurebayashi J; Otsuki T; Kunisue H; Tanaka K; Yamamoto S; Sonoo H
    Clin Cancer Res; 2000 Feb; 6(2):512-8. PubMed ID: 10690532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
    Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Vincent A; Vrancken Peeters MT; Nederlof PM; Wesseling J; Rodenhuis S
    Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An integrated analysis of genes and pathways exhibiting metabolic differences between estrogen receptor positive breast cancer cells.
    Mandal S; Davie JR
    BMC Cancer; 2007 Sep; 7():181. PubMed ID: 17883861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of body mass index and menopausal status with the intra-tumoral estrogen system in invasive breast cancer.
    Pfeiler G; Treeck O; Wenzel G; Goerse R; Hartmann A; Schmitz G; Ortmann O
    Gynecol Endocrinol; 2009 Mar; 25(3):183-7. PubMed ID: 19347708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative expression analysis of four breast cancer subtypes versus matched normal tissue from the same patients.
    Martini PG; Taylor DM; Bienkowska J; Jackson J; McAllister G; Keilhack H; Campbell RK
    J Steroid Biochem Mol Biol; 2008 Apr; 109(3-5):207-11. PubMed ID: 18424034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.